Hitgen: Advancing HDAC Inhibitors: DEL-Based Epigenetic Therapies Targeting c-MYC in Solid Tumors

June 12, 2025

 

MSQ CEO-Founder Webinar with Dr. Jin Li, Founder & CEO of HitGen Inc.

Join us for an exclusive conversation with Dr. Jin Li, Founder, Chairman & CEO of HitGen Inc. (SHA: 688222), a global leader in DNA encoded library (DEL) drug discovery.

Date/Time: Thurs June 12th at 9:00 AM ET / 9:00 PM BJT.
Host: Marc Estigarribia, Managing Director, MSQ Ventures (NYC)

Highlights:

  • Discover how HitGen’s DEL platform has scaled to over 1.2 trillion compounds and enabled 500+ global partnerships.

  • Hear Dr. Li’s insights on innovation, global alliances, and the future of small molecule drug discovery.

  • Audience Q&A on technology, pipeline, AI/ML integration, and strategic growth.